Cargando…
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
Autores principales: | Chen, Qitong, Ouyang, Dengjie, Anwar, Munawar, Xie, Ning, Wang, Shouman, Fan, Peizhi, Qian, Liyuan, Chen, Gannong, Zhou, Enxiang, Guo, Lei, Gu, Xiaowen, Ding, Boni, Yang, Xiaohong, Liu, Liping, Deng, Chao, Xiao, Zhi, Li, Jing, Wang, Yunqi, Zeng, Shan, Hu, Jinhui, Zhou, Wei, Qiu, Bo, Wang, Zhongming, Weng, Jie, Liu, Mingwen, Li, Yi, Tang, Tiegang, Wang, Jianguo, Zhang, Hui, Dai, Bin, Tang, Wuping, Wu, Tao, Xiao, Maoliang, Li, Xiantao, Liu, Hailong, Li, Lai, Yi, Wenjun, Ouyang, Quchang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974319/ https://www.ncbi.nlm.nih.gov/pubmed/33747972 http://dx.doi.org/10.3389/fonc.2021.661128 |
Ejemplares similares
-
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020) -
Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
por: Anwar, Munawar, et al.
Publicado: (2021) -
Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021) -
A literature review of the promising future of TROP2: a potential drug therapy target
por: Wen, Ying, et al.
Publicado: (2022) -
The Expression, Functions, Interactions and Prognostic Values of PTPRZ1: A Review and Bioinformatic Analysis
por: Xia, Zhenkun, et al.
Publicado: (2019)